In Focus: iPSCs for cell therapy
With their unlimited proliferation capacity and ability to differentiate into nearly any cell type in the body, induced pluripotent stem cells (iPSCs) have the potential to provide an unlimited supply of once-inaccessible human tissues for therapeutic applications. The development of allogeneic cell therapies derived from iPSCs offers the possibility of off-the-shelf treatments for many diseases, reducing the cost and complexity of current autologous cell therapies. The challenge now is scalability.
In this In Focus feature, we’ll be reviewing the current landscape of iPSC-based cell therapy manufacturing. We’ll also investigate the novel technologies that enable developers to successfully scale their cell therapies.
Infographic
Allogeneic iPSCs: getting ready for the future of cell therapy
This infographic highlights the advantages of iPSC-based allogeneic cell therapies and investigates the key requirements for successful manufacturing, including reproducibility and scale-up.
Interview
Strategies for enhancing allogeneic iPSC manufacture: an interview with Elena Matsa
In this interview, Elena Matsa, Vice President of Cell Technology at Cellistic (Gosselies, Belgium), explains the greatest challenges in the development of iPSC-based allogeneic cell therapy and reviews some of the available strategies and technologies to increase reproducibility and scalability and reduce costs in iPSC manufacturing.
In association with
